ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN) (“the Company” or “RegeneRx”) today announced that the abstract entitled Treatment of Acute Stroke With Thymosin ß4 has been honored with a score in the top 10 percent of all abstracts presented at the American Heart Association’s specialty conferences during the year, and therefore has been selected for re-presentation as a poster at the AHA’s Scientific Sessions on November 15. The Scientific Sessions will be held in Chicago from November 13 through 17.
